♟ My Largest Position Isn't What You Think

Why I'm Betting Big on Pfizer While Everyone Ignores 10x PE Healthcare Stocks ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in browser "By far, this is the most undervalued sector by almost every metric. It doesn't get any better than this." Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance Editor's Note: Bryan just cracked something big. After 25 years of trading, he's developed what might be the most accurate AI trading system I've ever seen. Cash Code X. 70% accuracy. 14X potential gains in three months. I've watched Bryan deliver 1,900+ winners at 76% accuracy in The War Room. But this AI breakthrough is different - it's spotting parabolic moves WEEKS before they happen. Join Bryan's Live Cash Code X Demo Wednesday, November 19 @ 2 p.m. ET He's doing a real-time scan during the event. You'll see the exact setups that delivered 1,200% stock gains and 1,463% options wins. Bryan's putting his 25-year reputation behind this system. REGISTER HERE Don't miss this one. - Ryan Fitzwater, Publisher Dear Reader, My single largest position is Pfizer (PFE). Yeah, you read that right. Bigger than even Seabridge Gold. I've been buying Pfizer for the last year, up and down, collecting that dividend, writing calls against it. It's cheap. And it's in - by far - the most undervalued sector by almost every metric. We're talking companies with P/Es around 10 or 11, paying dividends of 3.5% to 7% that are secure. It doesn't get any better than this. But while Pfizer's been a gold mine for my portfolio... I've now got my eye on one of its competitors. Pfizer just won the battle for Metsera - an obesity drug company that Novo Nordisk (NVO) wanted. But Novo is the better play here. They may have missed out on Metsera, but they've got the second-best obesity drug on the market with Wegovy. Pure Theatre You likely heard about Trump announcing a deal to bring down the prices of obesity drugs. Dr. Oz said we'd lose 135 billion pounds next year - that's 497 pounds per American. Sounds scary for drug companies, right? Wrong. They're lowering prices on the LOWEST doses. If you're really obese, you're not taking the lowest doses. You're still paying full freight. But here's the beautiful part: as part of this "price reduction," they expanded Medicare coverage for these drugs. SPONSORED Caught on Camera: Elon Musk’s “Area 51” You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see this footage.) A lot of people believe the U.S. government is hiding aliens at the highly classified U.S. Air Force facility in Nevada known as “Area 51.” But what’s happening inside Elon’s facility in Memphis is far more interesting. Click here to see the details because this could be the biggest military technology ever. Translation: "Yeah, we'll lower some prices, but we'll make it up on volume." They just expanded the market by millions of patients. That's why Novo Nordisk shares went UP on the "bad" news. It's all a charade. These pharma companies already know their margins. They know what they can sell for. The pharmacy benefit managers get their cut, the pharmacies get theirs - but now Medicare patients can access these drugs. The Setup for Next Week I'll probably be recommending a play in NVO to our paid subscribers next week. This company went from $150 to $49. Another pharma giant - Eli Lilly (LLY) - went from $600 to $900-plus. Lilly's probably going to break $1,000. But Novo has the infrastructure, the manufacturing capacity, and now the expanded market access. They're positioned to capture massive market share in what's becoming the biggest pharmaceutical opportunity of our lifetime. Why I'm Betting Big on Healthcare Look at what we're dealing with - Merck, Amgen, and AbbVie all trading at P/Es of 10-11. These companies have proven revenue streams, patent protection, and dividend coverage ratios that are bulletproof. Again, Pfizer's paying me 5%-plus while I wait. YOUR ACTION PLAN If you want to position yourself ahead of this healthcare rotation, start building positions in quality names trading at deep discounts. Companies like Pfizer, Merck, and Amgen are all sitting at levels where you can collect dividends while the market figures out what these companies are actually worth. I'm betting my largest position on it. INSIGHTS YOU MAY HAVE MISSED Weak Earnings? This Chart Is Still a Strong "Buy" Why Costco's -1% Performance Makes It My Top Post-Shutdown Play Trump's Next Big Move Could Spark a Massive Market Boom Seasonal Stocks Made Us $98/Share: Here's How We Timed It Perfect SPONSORED The ultimate trade for pickleball players If you play pickleball, golf, or any other sport... Then take a look at this one special trade. Imagine entering a trade at 9:30 a.m. ET... Collecting a HUGE profit a few minutes later... Closing your computer... And going about the rest of your day on the courts (or doing whatever else you want)! That's what is possible thanks to this lucrative 9:30 a.m. ET trade setup. Click here to learn it for yourself Monument Traders Alliance, LLC You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2025 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201. REF: 000133481441